OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd has announced that a major UK private insurance company will now reimburse the use of its OncoSil™ device at Imperial College Healthcare NHS Trust for treating locally advanced pancreatic cancer. This development is set to expand treatment access for patients and the company is looking to extend coverage with additional insurers. The OncoSil™ device, which provides targeted treatment in combination with chemotherapy, is part of OncoSil Medical’s global commercial strategy, already approved in over 30 countries.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
